SOX4表达与恶性黑素瘤临床病理特征及其转移的关系
|
摘要
目的探讨SOX4表达与恶性黑素瘤临床病理特征及其转移的相关性。方法选择恶性黑素瘤患者70例,同期收集正常皮肤组织30例作为对照组。免疫组织化学染色检测两组标本中SOX4阳性表达。比较两组的SOX4阳性积分。分析SOX4阳性积分与恶性黑素瘤临床病理特征的相关性。分析SOX4表达与恶性黑素瘤转移的关系。结果恶性黑素瘤患者的SOX4阳性表达积分明显高于对照组(P<0.01)。恶性黑素瘤组织SOX4阳性表达与年龄、性别无明显相关(P>0.05),与Breslow分级、Clark分级和溃疡形成显著相关(P<0.01)。3组恶性黑素瘤患者SOX4阳性表达率分别为69.23%、95.45%、100.00%,转移组明显高于原位组(P<0.01)。结论 SOX4在恶性黑素瘤组织中高表达,且与肿瘤的分期、进展及转移呈正相关。
Objective To investigate relationship of SOX4 expression and clinicopathologic characteristics and metastasis of malignant melanoma. Methods 70 patients with malignant melanoma were chosen,and 30 cases with normal skin tissue were the control group. Immunohistochemistry was employed to detect positive expression of SOX4 in the 2 groups. Score of SOX4 expression was compared between the 2 groups. Relationship of expression of SOX4 and clinical significance were analyzed. Relationship of SOX4 expression and metastasis of malignant melanoma was analyzed. Results Score of SOX4 expression in malignant melanoma was obviously higher than the control group( P < 0. 01). Expression of SOX4 was not related to gender and age of patient of malignant melanoma( P > 0. 05),and was significantly related to Breslow grade,Clark grade,and ulceration( P <0. 01). Positive expression rates of SOX4 of normal position,local metastasis,and distant metastasis were 69. 23%,95. 45%,100. 00%,respectively,and the metastasis group was evidently higher than normal position group( P < 0. 01). Conclusion SOX4 is highly expressed in malignant melanoma,it is positive correlated to clinical stage,development,and metastasis of malignant melanoma.
Objective To investigate relationship of SOX4 expression and clinicopathologic characteristics and metastasis of malignant melanoma. Methods 70 patients with malignant melanoma were chosen,and 30 cases with normal skin tissue were the control group. Immunohistochemistry was employed to detect positive expression of SOX4 in the 2 groups. Score of SOX4 expression was compared between the 2 groups. Relationship of expression of SOX4 and clinical significance were analyzed. Relationship of SOX4 expression and metastasis of malignant melanoma was analyzed. Results Score of SOX4 expression in malignant melanoma was obviously higher than the control group( P < 0. 01). Expression of SOX4 was not related to gender and age of patient of malignant melanoma( P > 0. 05),and was significantly related to Breslow grade,Clark grade,and ulceration( P <0. 01). Positive expression rates of SOX4 of normal position,local metastasis,and distant metastasis were 69. 23%,95. 45%,100. 00%,respectively,and the metastasis group was evidently higher than normal position group( P < 0. 01). Conclusion SOX4 is highly expressed in malignant melanoma,it is positive correlated to clinical stage,development,and metastasis of malignant melanoma.
引文
[1]马文宇,吴邓婷.中药植物多糖对恶性黑素瘤作用的实验研究进展[J].皮肤病与性病,2016,38(1):33-35.
[2]杨会杰,魏民,庞雅青,等.SOX4在乳腺癌组织中的表达及临床意义[J].中国现代普通外科进展,2014,17(6):459-461.
[3]刘辅仁.实用皮肤科学[M].北京:人民卫生出版社,2005:1044.
[4]Kanzler MH,Mraz-Gernhard S.Treatment of primary cutaneous melanoma[J].JAMA,2001,285(14):1819-1821.
[5]Bosman FT,de Goeij AF,Rousch M.Quality control in immunocytochemistry:experiences with the oestrogen receptor assay[J].J Clin Pathol,1992,45(2):120-124.
[6]Li W,Yu Y,Wang H,et al.Evaluation of the prognostic impact of postoperative adjuvant radiotherapy on head and neck mucosal melanoma:a meta-analysis[J].BMC Cancer,2015,15:758.
[7]张衍波,何梅芳,刘博武,等.恶性黑素瘤治疗和研究进展[J].中华保健医学杂志,2015,17(3):251-253.
[8]殷芳,吴飞,陈佳,等.TAMs在皮肤恶性黑素瘤组织中的浸润及与STAT3、VEGF蛋白表达的关系[J].中华全科医学,2013,11(6):840-843.
[9]陈燕辉,于建斌,张江安.VEGF-C在皮肤恶性黑素瘤中的表达及其意义[J].医药论坛杂志,2012,33(5):33-34.
[10]周璐,胡彬,黄莹雪,等.缺氧诱导因子1α在肢端恶性黑素瘤组织中的表达[J].中华皮肤科杂志,2014,47(9):615-618.
[11]黄莹雪,周璐,张耩,等.基质金属蛋白酶抑制剂4在皮肤恶性黑素瘤中的表达及其与肿瘤发生、侵袭和转移的相关性[J].中华皮肤科杂志,2013,46(8):565-569.
[12]董菲,孙成铭.SOX4在肿瘤中的研究进展[J].现代肿瘤医学,2016,24(9):1473-1476.
[13]潘欣,何昆,张维娜,等.SOX4能与p53蛋白发生相互作用[J].生物技术通讯,2008,19(6):817-819.
[14]梁鹏,陈学忠,宋建民,等.恶性黑素瘤的治疗进展[J].中华皮肤科杂志,2012,45(4):293-295.
[2]杨会杰,魏民,庞雅青,等.SOX4在乳腺癌组织中的表达及临床意义[J].中国现代普通外科进展,2014,17(6):459-461.
[3]刘辅仁.实用皮肤科学[M].北京:人民卫生出版社,2005:1044.
[4]Kanzler MH,Mraz-Gernhard S.Treatment of primary cutaneous melanoma[J].JAMA,2001,285(14):1819-1821.
[5]Bosman FT,de Goeij AF,Rousch M.Quality control in immunocytochemistry:experiences with the oestrogen receptor assay[J].J Clin Pathol,1992,45(2):120-124.
[6]Li W,Yu Y,Wang H,et al.Evaluation of the prognostic impact of postoperative adjuvant radiotherapy on head and neck mucosal melanoma:a meta-analysis[J].BMC Cancer,2015,15:758.
[7]张衍波,何梅芳,刘博武,等.恶性黑素瘤治疗和研究进展[J].中华保健医学杂志,2015,17(3):251-253.
[8]殷芳,吴飞,陈佳,等.TAMs在皮肤恶性黑素瘤组织中的浸润及与STAT3、VEGF蛋白表达的关系[J].中华全科医学,2013,11(6):840-843.
[9]陈燕辉,于建斌,张江安.VEGF-C在皮肤恶性黑素瘤中的表达及其意义[J].医药论坛杂志,2012,33(5):33-34.
[10]周璐,胡彬,黄莹雪,等.缺氧诱导因子1α在肢端恶性黑素瘤组织中的表达[J].中华皮肤科杂志,2014,47(9):615-618.
[11]黄莹雪,周璐,张耩,等.基质金属蛋白酶抑制剂4在皮肤恶性黑素瘤中的表达及其与肿瘤发生、侵袭和转移的相关性[J].中华皮肤科杂志,2013,46(8):565-569.
[12]董菲,孙成铭.SOX4在肿瘤中的研究进展[J].现代肿瘤医学,2016,24(9):1473-1476.
[13]潘欣,何昆,张维娜,等.SOX4能与p53蛋白发生相互作用[J].生物技术通讯,2008,19(6):817-819.
[14]梁鹏,陈学忠,宋建民,等.恶性黑素瘤的治疗进展[J].中华皮肤科杂志,2012,45(4):293-295.